Search for a trial

TOLERANCE: a 3 arm randomized study on healTh-related quality Of Life of EldeRly pAtients with advaNced soft tissue sarComa undergoing doxorubicin every three weeks or doxorubicin weekly or cyclophosphamide plus predniso(lo)ne treatment

Main objectiveThe primary objective of this study is to assess whether a higher HRQoL, in terms of impact of the disease and its treatment on physical and role functioning, is achieved with metronomic schedules of doxorubicin or cyclophosphamide…

MyKids: Molecular Identification and Characterization of non-Rhabdomyosarcoma Soft Tissue Sarcoma in Kids, Adolescents and Young Adults: an EpSSG NRSTS study

The MyKids study is a biological study towards the molecular profiling of pediatric NRSTS, the development of NRSTS tumoroid cultures, the establishment of liquid biopsy biomarkers and the molecular profiling of post-treatment tissue samples. The…

Brightline-1: A Phase II/III, randomized, openlabel, multi-center study of brigimadlin (BI
907828) compared to doxorubicin as first line treatment of patients with advanced
dedifferentiated liposarcoma.

This study has been transitioned to CTIS with ID 2024-511361-11-00 check the CTIS register for the current data. The trial will assess the efficacy and safety of brigimadlin compared to doxorubicin as first line systemic therapy for advanced or…

A Phase 2/3 Study to Evaluate the Efficacy and Safety of Unesbulin in Unresectable or Metastatic, Relapsed or Refractory Leiomyosarcoma

Primary:• Progression-free survival (PFS) of unesbulin plus dacarbazine (DTIC) versus placebo plus DTICSecondary:Efficacy:• Overall survival (OS) of subjects treated with unesbulin plus DTIC versus placebo plus DTIC• Antitumor activity of unesbulin…

A Phase 1/2 Dose Escalation and Dose Expansion Study of ZN-c3 in Combination with Gemcitabine in Adult and Pediatric Subjects with Relapsed or Refractory Osteosarcoma.

Primary:Phase 1: • To investigate the safety and tolerability, including identification of the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of ZN-c3 in combination with gemcitabinePhase 2: • To evaluate the clinical activity of…

Real-time margin assessment in head and neck cancer - enhancing specificity by combining fresh frozen sectioning with targeted fluorescence imaging
The LIGHTNING study

The main aim is to test whether cetuximab-IRDye800CW is a reliable marker for residual tumor remnants in resection margins after surgical removal of head and neck cancer. To increase the specificity of cetuximab-800CW, a specific frozen section can…